{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:05:35Z","timestamp":1780376735988,"version":"3.54.1"},"reference-count":68,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Triple-negative breast cancer is defined by the absence of druggable receptor targets and by a biologically dynamic phenotype that renders static, single-timepoint biomarker strategies fundamentally inadequate. Current predictive markers, including PD-L1 expression, tumor mutational burden, and genomic profiling, fail to capture the therapy-induced transcriptional reprogramming, spatial heterogeneity, and drug-tolerant persister states that drive resistance and relapse. In this review, we argue that RNA, particularly non-coding RNA (ncRNA), represents a complementary and state-aware platform for biomarker development in TNBC, capable of capturing transcriptional adaptation, regulatory threshold dynamics, and cell state transitions that static genomic markers cannot fully detect. Unlike messenger RNAs, which reflect active transcriptional programs, long non-coding RNAs and circular RNAs modulate the stability of state transitions and are specifically induced under conditions of therapeutic stress, immune exclusion, and drug tolerance, which are properties that make them suitable as potential early and sensitive indicators of adaptive reprogramming. We review the biological rationale for RNA as a state-aware readout across five dimensions: tumor plasticity, immune context, stress response, therapy adaptation, and microenvironment composition. An examination is conducted regarding how spatial transcriptomics can map RNA-defined resistant niches within TNBC, how serial liquid biopsy RNA measurements, including extracellular vesicle RNA and circulating tumor RNA, enable temporal monitoring of transcriptional state shifts before radiologic progression, and what analytical and clinical standards deployable RNA assays must meet. Finally, a state-guided adaptive management framework is proposed in which RNA signatures function as iteratively updated measurement layers informing therapy selection, on-treatment monitoring, and early resistance detection. This review outlines trial design models and defines the validation standards required before RNA-guided adaptation can enter clinical practice.<\/jats:p>","DOI":"10.3390\/ijms27114692","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:06:08Z","timestamp":1779465968000},"page":"4692","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["State-Aware RNA Biomarkers in Triple-Negative Breast Cancer (TNBC): Integrating Tumor Plasticity, Spatial Architecture, and Temporal Monitoring"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7362-789X","authenticated-orcid":false,"given":"Amal","family":"Qattan","sequence":"first","affiliation":[{"name":"Innovation and Research Division, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia"},{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13046-022-02476-1","article-title":"Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications","volume":"41","author":"Asleh","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Xiong, N., Wu, H., and Yu, Z. (2024). Advancements and challenges in triple-negative breast cancer: A comprehensive review of therapeutic and diagnostic strategies. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1405491"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ultimescu, F., Ardeleanu, C., Ginghina, O., Mardare, M., Zamfir, M., Puscasu, A.I., Bondoc, I., Vacarasu, A.-B., Antoniu, T., and Hudita, A. (2026). From Static to Dynamic: Adaptive Molecular Subtyping in Treated Breast Cancers\u2014Evidence from Single-Center Retrospective Cohort Study. Cancers, 18.","DOI":"10.20944\/preprints202601.0986.v1"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Wang, X., Collet, L., Rediti, M., Debien, V., De Caluw\u00e9, A., Venet, D., Romano, E., Roth\u00e9, F., Sotiriou, C., and Buisseret, L. (2023). Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges. J. Clin. Med., 12.","DOI":"10.3390\/jcm12030953"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Syeda, M.F., Santos, R.A., Sousa, L.M., Paiva, A.R., Branco, N.C., Pereira, T.C., Sousa, G., and Rodrigues-Santos, P. (2025). Immune monitoring of neoadjuvant chemo-immunotherapy for triple-negative breast cancer. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1654748"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s43856-025-00860-4","article-title":"Responses to checkpoint inhibition in metastatic triple negative breast cancer driven by divergent myeloid phenotypes","volume":"5","author":"Wilkerson","year":"2025","journal-title":"Commun. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10238-025-01892-9","article-title":"TMB as a predictive biomarker for ICI response in TNBC: Current evidence and future directions for augmented anti-tumor responses","volume":"26","author":"Das","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ende, N.S.v.D., Nguyen, A.H., Jager, A., Kok, M., Debets, R., and van Deurzen, C.H.M. (2023). Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032969"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Yuan, Y., Tang, Y., Fang, Z., Wen, J., Wicha, M.S., and Luo, M. (2025). Long Non-Coding RNAs: Key Regulators of Tumor Epithelial\/Mesenchymal Plasticity and Cancer Stemness. Cells, 14.","DOI":"10.3390\/cells14030227"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13058-025-01986-y","article-title":"Role of circulating tumor DNA in early-stage triple-negative breast cancer: A systematic review and meta-analysis","volume":"27","author":"Zhang","year":"2025","journal-title":"Breast Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/CCO.0000000000001180","article-title":"Circulating tumor DNA in early-stage triple-negative breast cancer: Clinical landscape and key open challenges","volume":"37","author":"Parsons","year":"2025","journal-title":"Curr. Opin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Barbi, V., De Martino, S., Aiello, A., Zamperla, M.G., Negri, S., Cis, L., Pecci, V., Nanni, S., Farsetti, A., and Martelli, F. (2025). Non-coding RNAs as novel biomarkers and therapeutic targets in breast cancer. Oncol. Rev., 19.","DOI":"10.3389\/or.2025.1621144"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Peng, J., Liu, W., Tian, J., Shu, Y., Zhao, R., and Wang, Y. (2025). Non-coding RNAs as key regulators of epithelial-mesenchymal transition in breast cancer. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1544310"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"112967","DOI":"10.1016\/j.intimp.2024.112967","article-title":"Chemotherapy-mediated lncRNA-induced immune cell plasticity in cancer immunopathogenesis","volume":"141","author":"Lu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kashyap, D., Sharma, R., Goel, N., Buttar, H.S., Garg, V.K., Pal, D., Rajab, K., and Shaikh, A. (2023). Coding roles of long non-coding RNAs in breast cancer: Emerging molecular diagnostic biomarkers and potential therapeutic targets with special reference to chemotherapy resistance. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.993687"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Perez-Medina, M., Benito-Lopez, J.J., Aguilar-Cazares, D., and Lopez-Gonzalez, J.S. (2025). A Comprehensive Review of Long Non-Coding RNAs in the Cancer\u2013Immunity Cycle: Mechanisms and Therapeutic Implications. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26104821"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41420-019-0190-6","article-title":"Long non-coding RNA (lncRNA) transcriptional landscape in breast cancer identifies LINC01614 as non-favorable prognostic biomarker regulated by TGF\u03b2 and focal adhesion kinase (FAK) signaling","volume":"5","author":"Vishnubalaji","year":"2019","journal-title":"Cell Death Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.21037\/tcr-23-1975","article-title":"A novel immune-related long noncoding RNA (lncRNA) pair model to predict the prognosis of triple-negative breast cancer","volume":"13","author":"Li","year":"2024","journal-title":"Transl. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1158\/0008-5472.CAN-25-0995","article-title":"Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients","volume":"86","author":"Baudre","year":"2026","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Davis, W.J.H., Drummond, C.J., Diermeier, S., and Reid, G. (2024). The Potential Links between lncRNAs and Drug Tolerance in Lung Adenocarcinoma. Genes, 15.","DOI":"10.3390\/genes15070906"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10142-025-01709-8","article-title":"Circular RNAs orchestrating breast cancer hallmarks: Bridging tumor biology and therapy resistance","volume":"25","author":"Abdelhamid","year":"2025","journal-title":"Funct. Integr. Genom."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1007\/s12672-025-03507-x","article-title":"Ferroptosis and non-coding RNAs in breast cancer: Insights into CAF and TAM interactions","volume":"16","author":"Saadh","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lee, W.-H. (2025). Special Issue \u201cRegulation by Non-Coding RNAs 2025\u201d. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262210885"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Cascione, L., Gasparini, P., Lovat, F., Carasi, S., Pulvirenti, A., Ferro, A., Alder, H., He, G., Vecchione, A., and Croce, C.M. (2013). Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055910"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1073\/pnas.1200010109","article-title":"Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA","volume":"109","author":"Volinia","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ncb1722","article-title":"The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1","volume":"10","author":"Gregory","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"14910","DOI":"10.1074\/jbc.C800074200","article-title":"The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional Repressors ZEB1 and ZEB2","volume":"283","author":"Korpal","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12943-018-0914-x","article-title":"The pro-metastasis effect of circANKS1B in breast cancer","volume":"17","author":"Zeng","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-013-2776-7","article-title":"Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer","volume":"142","author":"Thomassen","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08975","article-title":"Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis","volume":"464","author":"Gupta","year":"2010","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/0008-5472.CAN-12-2850","article-title":"The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells","volume":"73","author":"Gutschner","year":"2013","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1101\/gad.270959.115","article-title":"Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss","volume":"30","author":"Arun","year":"2015","journal-title":"Genes Dev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41419-019-1513-5","article-title":"Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness","volume":"10","author":"Shin","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13046-018-0945-6","article-title":"Long noncoding RNA LINC00511 contributes to breast cancer tumourigenesis and stemness by inducing the miR-185-3p\/E2F1\/Nanog axis","volume":"37","author":"Lu","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7065","DOI":"10.1158\/0008-5472.CAN-05-1783","article-title":"MicroRNA gene expression deregulation in human breast cancer","volume":"65","author":"Iorio","year":"2005","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.1158\/0008-5472.CAN-05-0137","article-title":"MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells","volume":"65","author":"Chan","year":"2005","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/cdd.2009.56","article-title":"The miR-34 family in cancer and apoptosis","volume":"17","author":"Hermeking","year":"2010","journal-title":"Cell Death Differ."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm.2284","article-title":"The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44","volume":"17","author":"Liu","year":"2011","journal-title":"Nat. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"29897","DOI":"10.1074\/jbc.M804612200","article-title":"MicroRNA-221\/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1","volume":"283","author":"Miller","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1038\/onc.2014.378","article-title":"Tumor hypoxia induces nuclear paraspeckle formation through HIF-2\u03b1 dependent transcriptional activation of NEAT1 leading to cancer cell survival","volume":"34","author":"Choudhry","year":"2015","journal-title":"Oncogene"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"11125","DOI":"10.1007\/s00210-025-04057-3","article-title":"Mapping molecular landscapes in triple-negative breast cancer: Insights from spatial transcriptomics","volume":"398","author":"Almasoudi","year":"2025","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Han, X., Li, X., Bai, L., and Zhang, G. (2025). Single-cell transcriptomics in metastatic breast cancer: Mapping tumor evolution and therapeutic resistance. Front. Genet., 16.","DOI":"10.3389\/fgene.2025.1669741"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sadovska, L., Zayakin, P., Egl\u012btis, K., Endzeli\u0146\u0161, E., Radovi\u010da-Spalvi\u0146a, I., Avoti\u0146a, E., Auders, J., Kei\u0161a, L., Liepniece-Karele, I., and Leja, M. (2022). Comprehensive characterization of RNA cargo of extracellular vesicles in breast cancer patients undergoing neoadjuvant chemotherapy. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1005812"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41523-021-00356-z","article-title":"Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer","volume":"7","author":"Su","year":"2021","journal-title":"npj Breast Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.7150\/ijms.119142","article-title":"Dual-Function RNA Biomarkers: Integrating Relapse Prediction and Immune Profiling in Triple-Negative Breast Cancer","volume":"22","author":"Wen","year":"2025","journal-title":"Int. J. Med. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Brogna, M.R., Ferrara, G., Varone, V., Montone, A., Fava, A., Schiano, M.R., Del Sesto, M., Pizza, N., Prota, A., and Barra, C. (2026). Liquid biopsy in triple-negative breast cancer: A promising tool for diagnosis, prognosis, and treatment monitoring. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1642521"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Simancas-Racines, D., Rom\u00e1n-Galeano, N.M., V\u00e1squez, J.P., Gavilanes, D.J., Vijayan, R., and Reytor-Gonz\u00e1lez, C. (2025). Liquid Biopsy and Multi-Omic Biomarkers in Breast Cancer: Innovations in Early Detection, Therapy Guidance, and Disease Monitoring. Biomedicines, 13.","DOI":"10.3390\/biomedicines13123073"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1038\/s41467-025-57988-z","article-title":"Dynamic ctDNA tracking stratifies relapse risk for triple negative breast cancer patients receiving neoadjuvant chemotherapy","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"10232","DOI":"10.1038\/s41467-024-54145-w","article-title":"Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"zcae046","DOI":"10.1093\/narcan\/zcae046","article-title":"Spatial transcriptomics in breast cancer reveals tumour microenvironment-driven drug responses and clonal therapeutic heterogeneity","volume":"6","year":"2024","journal-title":"NAR Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s44272-024-00018-8","article-title":"Spatial transcriptomics: A new frontier in cancer research","volume":"3","author":"Huang","year":"2024","journal-title":"Clin. Cancer Bull."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/0008-5472.CAN-22-2682","article-title":"Spatial Transcriptomic Analysis of a Diverse Patient Cohort Reveals a Conserved Architecture in Triple-Negative Breast Cancer","volume":"83","author":"Bassiouni","year":"2023","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Chen, S.-L., Fei, Y.-R., Cai, X.-X., Wang, C., Tong, S.-Y., Zhang, Z.-Z., Huang, Y.-X., Bian, D.-D., He, Y.-B., and Yang, X.-X. (2025). Exploring the role of metabolic pathways in TNBC immunotherapy: Insights from single-cell and spatial transcriptomics. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1528248"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1016\/j.cell.2024.09.001","article-title":"Spatially exploring RNA biology in archival formalin-fixed paraffin-embedded tissues","volume":"187","author":"Bai","year":"2024","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41698-024-00728-1","article-title":"Discovery of prognostic lncRNAs in colorectal cancer using spatial transcriptomics","volume":"8","author":"Pinkney","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Kim, J.-Y., Park, K., La Choi, Y., Lee, J.E., Chae, B.J., Yu, J., Kim, S.W., Nam, S.J., Ahn, J.S., and Park, W.-Y. (2024). Abstract 1149: Spatial transcriptomic analysis of tumor microenvironment in patients with triple negative breast cancer with residual disease after neoadjuvant chemotherapy with immune checkpoint inhibitor. Cancer Res., 84.","DOI":"10.1158\/1538-7445.AM2024-1149"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1631\/jzus.B2200206","article-title":"Spatial transcriptome analysis of long non-coding RNAs reveals tissue specificity and functional roles in cancer","volume":"24","author":"Xu","year":"2023","journal-title":"J. Zhejiang Univ. B"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1111\/cas.15155","article-title":"Multi-miRNA panel of tumor-derived extracellular vesicles as promising diagnostic biomarkers of early-stage breast cancer","volume":"112","author":"Kim","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"117480","DOI":"10.1016\/j.biopha.2024.117480","article-title":"Unlocking the potential of extracellular vesicle circRNAs in breast cancer: From molecular mechanisms to therapeutic horizons","volume":"180","author":"Fang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Zayakin, P., Sadovska, L., Egl\u012btis, K., Romanchikova, N., Radovi\u010da-Spalvi\u0146a, I., Endzeli\u0146\u0161, E., Liepniece-Karele, I., Egl\u012btis, J., and Lin\u0113, A. (2023). Extracellular Vesicles\u2014A Source of RNA Biomarkers for the Detection of Breast Cancer in Liquid Biopsies. Cancers, 15.","DOI":"10.3390\/cancers15174329"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/1878-0261.70101","article-title":"Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow-up biomarkers for breast cancer","volume":"20","author":"Rajan","year":"2025","journal-title":"Mol. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1158\/0008-5472.CAN-15-3284","article-title":"Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value","volume":"76","author":"Jiang","year":"2016","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s13353-024-00876-x","article-title":"The analysis of transcriptomic signature of TNBC\u2014Searching for the potential RNA-based predictive biomarkers to determine the chemotherapy sensitivity","volume":"66","author":"Supplitt","year":"2025","journal-title":"J. Appl. Genet."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines","volume":"7","author":"Witwer","year":"2018","journal-title":"J. Extracell. Vesicles"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Das, K., Paul, S., Ghosh, A., Gupta, S., Mukherjee, T., Shankar, P., Sharma, A., Keshava, S., Chauhan, S.C., and Kashyap, V.K. (2023). Extracellular Vesicles in Triple\u2013Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential. Cancers, 15.","DOI":"10.3390\/cancers15194879"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Be\u0148a\u010dka, R., Szab\u00f3ov\u00e1, D., Gu\u013ea\u0161ov\u00e1, Z., and Hertelyov\u00e1, Z. (2024). Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26010127"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e19063","DOI":"10.7717\/peerj.19063","article-title":"Development of a prognostic model based on the ceRNA network in Triple-Negative Breast cancer","volume":"13","author":"Zhu","year":"2025","journal-title":"PeerJ"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40478-024-01769-0","article-title":"Spatial transcriptomics reveals segregation of tumor cell states in glioblastoma and marked immunosuppression within the perinecrotic niche","volume":"12","author":"Liu","year":"2024","journal-title":"Acta Neuropathol. Commun."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/4692\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:17:12Z","timestamp":1780373832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/4692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":68,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27114692"],"URL":"https:\/\/doi.org\/10.3390\/ijms27114692","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]}}}